Cutera granted FDA nod for AviClear for long-term acne therapy

• Medical equipment maker Cutera (NASDAQ:CUTR) announced Thursday that the FDA greenlighted its AviClear laser device as a long-term treatment option for mild, moderate, and severe acne.
• The FDA OK’ed Aviclear in March 2022, making it the first and only energy-based device to receive the agency’s 510(k) clearance to treat mild, moderate, and severe acne.
• After three 30-minute treatment sessions, AviClear is found to have visibly improved acne in 90% of patients six months after their third treatment session.
• Highlighting the long-term efficacy of AviClear, Cutera (CUTR) said that the improvement rate has risen to 92% after 12 months.
• Aviclear is a prescription-free option designed to suppress the sebaceous glands. Overproduction of sebum from sebaceous glands is a leading cause of acne.

More on Cutera

• Cutera new advisor Taylor Harris said to be likely CEO candidate
• Cutera: A Mix Of Positives And Negatives